Treatment of complicated benign prostatic hyperplasia with LHRH‐analogues in aged patients

Abstract
The effect of administration of an LHRH‐analogue (LHRH‐a) was evaluated in 11 patients with benign prostatic hyperplasia (BPH) in whom there were contraindications for surgery. These patients, who already had impaired potency due to age or serious illness, were given 1500 μg LHRH‐a in the first week and 1200 μg from the eighth day onwards. They all improved significantly (P < 0.001) with regard to their urological symptoms on day 60 of treatment. Our results demonstrate the influence of androgen in maintaining established BPH, the effectiveness of LHRH‐a therapy in selected patients with BPH and the usefulness of a salivary testosterone assay for the follow‐up of treatments expected to lower the bioavailability of androgen to target tissues.

This publication has 8 references indexed in Scilit: